We showed that adding celecoxib to a current standard-of-care treatment, encorafenib (BRAF inhibitor) + panitumumab (EGFR inhibitor)5, resulted in sustainable and significant tumor growth inhibition in BRAFV600E CRC PDXs. This evidence concerns the gene EGFR and neoplasm.